Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4703 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4704 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5091 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
filingDate |
2006-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b116d76221cb23dae04d126679435ded http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4682acf0855723012f3e7389cb8bf1c4 |
publicationDate |
2006-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CA-2604983-A1 |
titleOfInvention |
Biomarker for sensitivity to mtor inhibitor therapy in kidney cancer |
abstract |
The invention disclosed herein provides methods for the examination and/ or quantification of biochemical pathways that are disregukted in pathologies such as cancer and to reagents and kits adapted for performing such methods. For example a correlation between VHL loss and mTOR inhibitor sensitivity in human kidney cancer cells is disclosed, indicating that VHL loss confers autonomous and angiogenic competitive advantages to such cells. |
priorityDate |
2005-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |